Sun Pharmaceutical (NSE:SUNPHARMA) won South African approval to ship generic semaglutide pens for adults with uncontrolled type 2 diabetes in days, while analysts flag the stock as a Buy with a 2,080 target amid a weekly uptrend and 1,880 near‑term support.
Previous Week Recap
- Sun Pharma Clears South Africa: Sun Pharma cleared by South Africa regulator to launch generic semaglutide pens (2 mg, 4 mg) for adults with uncontrolled type 2 diabetes; product to ship to South African market in days.
- Sun Pharma Buy Target 2080: Sun Pharma (SUNPHARMA) flagged as Buy; price target 2,080, stop-loss 1,880. Weekly uptrend with higher highs/lows, recent rebound from trendline support. RSI supportive; 1,880 is near-term key level.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.